KRAS mutated lung cancer is no longer untreatable - the latest clinical and drug purchasing guide for Sotorasib

1. Hot Spots:KRASMutation-targeted drugs have attracted global attention

In the past few decades, the KRAS mutation has been called an "undruggable gene." The scientific community has invested countless efforts to overcome this mutation, but has repeatedly suffered setbacks. However, in 2021, the U.S. FDA approved the world's first KRAS G12C inhibitor - Sotorasib (trade name: Lumakras), officially rewriting the history of targeted tumor therapy.

Now, with the release of more real-world clinical data, this drug has once again become the focus of the oncology field from 2024 to 2025 . KRAS G12CThe proportion of mutations in non-small cell lung cancer (NSCLC) is about 13%, and it is also found in colorectal cancer and pancreatic cancer. The emergence of sotoracib not only brings hope to these "neglected" patients, but also marks the successful breakthrough of "undruggable targets".

The attention of Chinese academic circles and patient groups continues to rise. On multiple cancer forums and patient social platforms, "KRAS G12CTest" and "Sotorasib Drug Purchase Guide" have become hot search topics.

2. Overview of the drug: What is sotoracib?

Sotorasib (Sotorasib) was developed by Amgen (Amgen) and is the world's first KRAS G12C targeted inhibitor approved for marketing. The drug irreversibly binds to the KRAS G12C mutated protein, blocking its conversion to the activated state, thereby inhibiting the downstream MAPK and PI3K signaling pathways and preventing the proliferation and spread of tumor cells.

In other words, the mechanism of action of sotorasibu is to "turn off the switch of cancer cells." This precise design allows the drug to act specifically on KRAS G12C mutated cells without affecting normal cells, thereby significantly reducing toxic side effects.

Today, with the booming development of molecular targeted drugs, sotoraxib is considered another milestone innovative drug in "precision medicine".

3. Clinical research results: the real efficacy data is exciting

The pivotal registration study of sotoraxib——CodeBreaK 100 trial can be called a milestone study of KRAS targeted drugs.

The study included 124patients with KRAS G12C mutated non-small cell lung cancer (NSCLC). The results show:

The objective response rate (ORR) is37%;

The disease control rate (DCR) is as high as 81%;

The median progression-free survival (PFS) is 6.8 months;

Some patients' tumors shrank by more than 80%, and the lesions disappeared significantly.

It is worth noting that in the subsequent CodeBreaK 200 III phase trial, sotoracib performed better than docetaxel:

The efficacy significantly prolongs survival;

Toxic reactions are more controllable;

The patient's quality of life was significantly improved.

In addition, sotorasibu has shown potential in colorectal cancer, pancreatic cancer and other solid tumors, with some patients achieving long-term remission. This means that the field of KRAS targeted therapy is being continuously expanded.

4. Indications and Medication Guide

1.Indications:

Currently, sotoracib is mainly used to treat adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) carrying KRAS G12C mutations, and the patients are required to have received at least one systemic treatment (such as chemotherapy or immunotherapy). Also used to treat adult patients with KRAS G12C mutated locally advanced or metastatic colorectal cancer.

2.Usage and dosage:

Recommended dosage:960mg/day (orally),once a day;

Can be taken with water, before or after meals;

If adverse reactions (such as diarrhea, nausea or abnormal liver function) occur, the dose can be reduced to 480mg or 240mg/ days under the guidance of a doctor.

3.Notes:

Avoid co-administration with strongCYP3A4 inducers (such as rifampin) to avoid reducing drug efficacy;

Liver function and blood routine tests need to be checked regularly during use;

Contraindicated for pregnant or lactating women;

If you develop a rash or difficulty breathing, seek medical attention immediately.

Treatment with sotoraxib is usually long-term oral maintenance until disease progression or tolerability issues arise.

5. Drug efficacy and safety analysis

The clinical efficacy of sotoracib is not only reflected in the tumor shrinkage rate, but more importantly, the improvement of patients' quality of life. According to multiple real-world reports:

Most patients’ symptoms improve significantly within 2-4 weeks of taking the medicine;

Dyspnea, cough and chest pain were significantly relieved;

Physical strength, appetite and sleep status are improved.

In terms of side effects, sotoraxib was generally well tolerated. Common adverse reactions include:

Diarrhea (42%);

Nausea (26%);

Transaminase elevation (20%around);

A small number of patients experience mild fatigue or dry mouth.

Most of these side effects are reversible and can be resolved by adjusting the dose or briefly discontinuing the drug. Compared with traditional chemotherapy or immunotherapy, the safety profile of sotoraxib is significantly better.

6. Overseas sales and price information

At present, sotorasibu is not available in mainland China, so patients cannot purchase it through domestic pharmacies or hospitals. However, the drug can be obtained through legal overseas channels (such as Hong Kong, Europe and Laos).

According to market data:

Original drug price (European version/Hong Kong version): 120mg×56The selling price of tablet specifications is about tens of thousands of yuan, which may fluctuate between5ten thousand to9ten thousand yuan in different regions;

Generic drug prices (Lao version): Laos Lucius and Laos Daxiong have launched legally marketed generic drugs of sotorasibu, 120mg×56 tablets only cost more than 1,000 yuan;

Comparison of drug ingredients: The active ingredients of generic drugs and original drugs are basically the same, and both are the active molecules of sotolaxib.

For patients undergoing long-term treatment, the Laos generic version will undoubtedly greatly reduce the economic burden and give more people the opportunity to receive targeted therapy.

Seven. Real cases and clinical experience

In published clinical and real-world reports, many patients experienced significant improvements after taking sotorasiib:

A KRAS G12C mutated lung cancer patient from Singapore, after taking the drug for 3 weeks, the tumor shrank by 50%, and the lesions were clearly reduced on imaging review;

A 60 male patient in Los Angeles, USA, his condition has been stable for more than a year after taking sotoraxib;

Feedback from patients who have used this drug in Hong Kong, China:“The side effects are controllable, and coughing and shortness of breath were significantly relieved within a month.”

These real-life cases further verify the clinical value of sotoraxib and provide treatment experience that can be used for more KRAS mutation patients.

From“no medicine available” to “precise control”, the birth of Sotorasibu is a major victory for modern medicine. It makes the KRAS mutation no longer a label of despair, but a manageable chronic disease. Although it has not yet been launched in China, patients can still get treatment opportunities through reasonable channels and scientific use of medicines. With the advancement of policies and in-depth research and development, sotorasibu will truly enter the lives of more patients in the future and help them achieve a longer and higher-quality life.

xa0

References:

1.Hong DS et al. Sotorasib for Lung Cancers with KRAS p.G12C Mutation. N Engl J Med. 2020;383:1207–1217.

2.Amgen Official Product Information – https://www.amgen.com

3.FDA Drug Approval Document for Lumakras – https://www.fda.gov

4.ESMO 2024 Congress KRAS G12C Update Report – https://www.esmo.org

5.NCCN Guidelines 2025 – Non-Small Cell Lung Cancer Section

6.ClinicalTrials.gov – CodeBreaK 100/200 Trial Data